Barr Strikes Back At Celgene In Thalomid Spat

Law360, New York (October 11, 2007, 12:00 AM EDT) -- Barr Laboratories has fired back at Celgene Corp. in a patent suit over the market for Celgene's cancer treatment Thalomid, alleging that Celgene's patents are invalid and accusing Celgene of violating the Sherman Act by impeding Barr's efforts to market generic thalidomide.

On Wednesday, Barr filed its answer and counterclaims in the U.S. District Court for the District of New Jersey. Celgene filed an amended complaint in the case on Oct. 2, adding a composition patent issued in June. The case was originally lodged in January...
To view the full article, register now.